Weight Regain After Stopping GLP-1s: A New 2026 Trial Shows Support Programs Cut It by Two-Thirds

Researchers led by Kelseanna Hollis-Hansen of the Tufts University Food is Medicine Institute, working with colleagues at UT Southwestern Medical Center, enrolled 39 adults who had lost weight on GLP-1 therapy and randomized them at the moment they discontinued the medication. The results were published October 7, 2026 in Obesity Science & Practice.

Each participant was assigned to one of three groups for four months: usual care (no added support), a digital wellness app they were asked to use at least 15 minutes a day, or medically tailored meals — participants chose 10 prepared meals per week from a menu of 70.

The gap between the groups was striking. According to the published results, the usual-care group regained an estimated 10.75% of body weight in just four months. The app group regained about 3.60%, and the tailored-meals group about 3.58% — roughly one-third of the regain seen with no support.

None of this means GLP-1 medications "don't work." It means obesity behaves like the chronic condition it is. GLP-1 medications quiet appetite signals and food noise while you take them; when the medication stops, biology pushes back. As Newsweek's coverage of the trial notes, prior research reviewing almost 40 studies found that people regained about a pound per month after stopping, on a trajectory to regain what they had lost within roughly two years.

That is the backdrop that makes this pilot genuinely useful: it is one of the first randomized tests of what to do about the off-ramp, rather than another study documenting that the off-ramp is steep.

Two details of the trial are worth noticing, because they are things real patients can actually replicate.

First, the support did not need to be exotic. One arm was simply a wellness app used daily — tracking, habit prompts, and engagement for at least 15 minutes a day. The other was prepared, portion- and nutrition-controlled meals delivered weekly. Both produced nearly identical results.

Second, the support started on day one of stopping, not after the scale had already moved. The participants were randomized at discontinuation, which suggests the transition window itself is the moment that matters. If you and your provider ever plan to stop or pause a GLP-1, the maintenance plan should be in place before the last dose — a point we cover in depth in our guide to maintaining weight loss after GLP-1 medications.

This was a pilot trial: 39 people across three groups, followed for four months. That is large enough to see a signal and small enough that the exact percentages should be held loosely. The authors reported that diet quality, perceived health, adherence, and satisfaction did not differ significantly between groups, and larger, longer trials are needed before anyone can say precisely how much regain structured support prevents at one or two years.

It is also not a reason to stop a medication that is working. Major guidelines increasingly treat anti-obesity medication as long-term therapy, and the decision to continue, taper, or stop belongs in a conversation with a licensed provider who knows your history — not in a headline.

A few practical takeaways for patients:

If you're doing well on treatment, this study is not a push to stop. It is evidence that if you ever need to stop — because of cost, access, side effects, or a planned pause — regain is not inevitable at full speed. Structure changes the slope.

If you're considering starting, plan for the whole arc, not just the losing phase. Ask how your program handles maintenance, dose adjustments, and support between visits. GLP-1s commonly cause nausea, vomiting, diarrhea, or constipation, especially during dose increases, and they are not appropriate for everyone — including people with a personal or family history of medullary thyroid carcinoma or MEN 2 — which is why screening by a licensed provider matters.

If you've stopped recently, the trial suggests the next few months are the window where daily structure earns its keep: consistent tracking, planned meals, protein, and movement.

JoeyMed's weight loss program is built around that whole arc. A licensed provider reviews your health history and labs, determines whether treatment such as compounded tirzepatide (Tirz HD) is appropriate for you, and stays with you through titration, side-effect management — including anti-nausea support when you need it — and the maintenance conversation this new research shows is so important. Treatment decisions are always made with your provider, results vary from person to person, and no medication is a guarantee — but you should never have to figure out the off-ramp alone.